Previous close | 0.7018 |
Open | 0.6802 |
Bid | 0.6979 x 200 |
Ask | 0.7384 x 200 |
Day's range | 0.6802 - 0.7104 |
52-week range | 0.6710 - 5.9500 |
Volume | |
Avg. volume | 1,365,156 |
Market cap | 28.848M |
Beta (5Y monthly) | 2.53 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.2400 |
Earnings date | 13 May 2024 - 17 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 2.75 |
SOUTH SAN FRANCISCO, Calif., April 22, 2024--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that a submitted abstract was accepted for poster presentation at the Pediatric Endocrine Society (PES) 2024 Annual Meeting taking place May 2-5, 2024, in Chicago, IL.
Spruce Biosciences (SPRB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
The latest analyst coverage could presage a bad day for Spruce Biosciences, Inc. ( NASDAQ:SPRB ), with the analysts...